This type of intracellular immunization has potential for use in treating HIV-1 infected individuals through stem cell genome editing approaches wherein all subsequently progeny CD4+ T cells will express the anti-viral VH and thus would be impervious to continued HIV-1 infection. Here, CD4 is linked to HIV-1 infection.